Display options
Share it on

Breast Care (Basel). 2013 Aug;8(4):276-81. doi: 10.1159/000354125.

Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?.

Breast care (Basel, Switzerland)

Ayotunde J Fasunla, Nadia Harbeck, Barbara Schmalfeld, Sabina Berktold, Christina Böhner, Walter Hundt, Petra Wolf, Silke Steinbach

Affiliations

  1. Department of Otorhinolaryngology, Philipps-University, Marburg, Germany ; Department of Otorhinolaryngology, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria, Germany.
  2. Breast Centre, Ludwig-Maximilians University, Munich, Germany.
  3. Department of Obstetrics and Gynaecology, Women's Hospital Rechts der Isar, Germany.
  4. Department of Radiology, Philipps-University, Marburg, Germany.
  5. Institute of Medical Statistics and Epidemiology, Hospital Rechts der Isar, Technical University Munich, Germany.
  6. Department of Otorhinolaryngology, Philipps-University, Marburg, Germany.

PMID: 24415980 PMCID: PMC3808219 DOI: 10.1159/000354125

Abstract

BACKGROUND: Our objective was to assess the auditory function of gynaecological tumour patients who had received cytotoxic agents and to determine their associated risk of ototoxicity.

PATIENTS AND METHODS: 87 patients who had undergone chemotherapy for gynaecological malignancies were investigated. Of these patients, 79% had breast cancer, and 14% ovarian cancer. All of the patients had a subjective assessment of their hearing function on a visual analogue scale. Audiometric tests were performed before and at 9 weeks, 18 weeks and 3 months after completion of chemotherapy.

RESULTS: The age of the patients ranged from 32 to 71 years (mean age of 53.5 ± 10.5 years). The average subjective rating of the patients' hearing function was 83.0 ± 17.2 before and 84.8 ± 16.9 3 months after completion of chemotherapy. No significant audiometric change at either the speech hearing frequency range (0.5-2 KHz) or high frequencies was observed in the patients after chemotherapy. There was also no significant difference in the hearing threshold of the patients who had received platinum analogue-based chemotherapy compared to non-platinum analogue-based chemotherapy.

CONCLUSION: Hearing loss is uncommon in patients treated with the typical gynaecological chemotherapy protocols. Hence, routine audiometric testing in these patients is not necessary.

Keywords: Breast cancer; Chemotherapy; Hearing function; Ovarian cancer

References

  1. Breast. 2009 Oct;18(5):279-83 - PubMed
  2. Otol Neurotol. 2004 May;25(3):353-8 - PubMed
  3. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1990 Aug;25(4):195-8, 254 - PubMed
  4. Scand Audiol. 1988;17(4):241-7 - PubMed
  5. Ann Oncol. 2002 Mar;13(3):374-84 - PubMed
  6. Ear Hear. 1991 Apr;12(2):91-102 - PubMed
  7. Med Oncol. 2000 Nov;17(4):287-92 - PubMed
  8. J Laryngol Otol. 1993 Jul;107(7):585-9 - PubMed
  9. J Clin Oncol. 2006 Feb 20;24(6):918-24 - PubMed
  10. Acta Otorhinolaryngol Ital. 2008 Oct;28(5):239-42 - PubMed
  11. Breast. 2006 Jun;15(3):448-51 - PubMed
  12. Breast Care (Basel). 2009;4(2):75-80 - PubMed
  13. Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):913-9 - PubMed
  14. Braz J Otorhinolaryngol. 2009 Sep-Oct;75(5):634-41 - PubMed
  15. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 - PubMed
  16. Br J Cancer. 1996 Apr;73(8):979-84 - PubMed
  17. Acta Otolaryngol. 1986 Jan-Feb;101(1-2):66-74 - PubMed
  18. Gerontology. 2010;56(3):351-8 - PubMed
  19. Audiol Neurootol. 2006;11(5):318-30 - PubMed
  20. Clin Obstet Gynecol. 2011 Mar;54(1):157-63 - PubMed

Publication Types